756520-67-9

Basic information

• Product Name: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine
• Synonyms: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine;2-PyridinaMine, 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-;[3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]pyridin-2-yl]amine
• CAS NO: 756520-67-9
• Molecular Formula: C₁₃H₁₁Cl₂FN₂O
• Molecular Weight: 301.1436432
• Mol File: 756520-67-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 408.5°C at 760 mmHg
• Flash Point: 200.8°C
• Appearance: /
• Density: 1.4g/cm³
• Vapor Pressure: 6.98E-07mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine(756520-67-9)
• EPA Substance Registry System: 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine(756520-67-9)

Safety Data

• Hazardous Substances Data: 756520-67-9(Hazardous Substances Data)

Usage

General Description

3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine is a complex organic compound with potential applications in research and manufacturing sectors. The key structural components of this compound include a pyridine ring, an ethoxy group, and a phenyl ring that is halogenated with chlorine and fluorine atoms. The detailed properties of this compound including its physical and chemical properties, reactivity, and potential safety hazards are generally determined using various analytical and spectroscopic methods. While information specific to this chemical is limited, it is likely that scientists and researchers studying the phenomena of halogenation, organic synthesis, or the bioactive properties of substituted pyridine molecules may find it particularly useful.

InChI:InChI=1/C13H11Cl2FN2O/c1-7(19-10-3-2-6-18-13(10)17)11-8(14)4-5-9(16)12(11)15/h2-7H,1H3,(H2,17,18)

Upstream product

• 1229457-91-3 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 756521-08-1 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine 

Downstream Products

• 756508-98-2 6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-nicotinonitrile 
• 756503-69-2 (±)-5-bromo-3-(1-(2,6-dichloro-3-fluoropheny)ethoxy)pyridin-2-amine 
• 1428476-85-0 tert-butyl 4-(4-(5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-6-(ethylamino)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1428476-72-5 3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-ethyl-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine 
• 1428476-71-4 N-(3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(1-ethylpiperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-yl)acetamide 
• 1421270-66-7 C₂₂H₂₂Cl₂FN₅O*CH₂O₂ 
• 1421270-71-4 (±)-tert-butyl 6-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate 
• 877401-42-8 tert-butyl 4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 877400-66-3 (+/-)-PF023401066 

Relevant articles and documents

Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants

Despite the initial benefit demonstrated in clinical setting with ALK inhibitors, the challenging resistant mutants (F1174L, L1196M and G1202R) invariably developed. In this work, a series of 2-aminopyridine derivatives were designed and synthesized by C-5 position incorporation of a 2-pyridone moiety and bioisosteric replacement of the C-3 position linkers. Optimization of the 2-aminopyridine derivatives led to the identification of hit 18d displaying a significant growth inhibition against a variety of ALK-addicted cancer cells. Especially in the case of ALK-positive Karpas-299 cell, 18d exhibited excellent anti-proliferative potency with an IC50 value of about 40 nM. Moreover, 18d demonstrated encouraging activities against wild-type ALK (19 nM), ROS1 (2.3 nM) as well as challenging crizotinib-resistant ALKL1196M and ALKG1202R mutants with IC50 values of 45 nM and 22 nM, respectively. Additionally flow cytometric analysis indicates that 18d inhibited Karpas-299 cell viability via G1 phase arrest. Taken together, this work provided a promising ALK inhibitor to circumvent the clinical crizotinib-resistant mutants.

Method for preparing Crizotinib chiral intermediate

The invention relates to a method for preparing a Crizotinib chiral intermediate, which belongs to the field of medicine synthesis. The preparation method of the intermediate (1) is characterized in that chiral organic acidity is taken as a resolving agen

AMINO HETEROARYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention refers to aminoheteroaryl compounds of the following formula (I) as well as the preparation method and use thereof, wherein R1 and R3 are defined in the Description in details. The aminoheteroaryl compounds of t